Abstract

Antagonists and synthesis inhibitors of several proposed mediators in asthma have been investigated in humans. Drugs blocking histamine, thromboxane A2, and platelet-activating factor have either shown no activity or their activity has been too limited to be of clinical relevance. In contrast, for drugs affecting the leukotriene pathway, there is now extensive evidence demonstrating clinically important effects in preventing antigen- and …